Pierantonio L. Menna

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Correspondence on Mauro et al.: ensuring meaningful conclusions through data accuracy and consistency.

Correspondence on Mauro et al.: ensuring meaningful conclusions through data accuracy and consistency.

Journal: Leukemia

Published: June 13, 2026

Bruton tyrosine kinase inhibitors and cardiovascular adverse events.

Bruton tyrosine kinase inhibitors and cardiovascular adverse events.

Journal: British journal of pharmacology

Published: March 28, 2026

Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies.

Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies.

Journal: Mediterranean journal of hematology and infectious diseases

Published: December 15, 2025

Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

Journal: Leukemia

Published: December 02, 2025

Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

Journal: Leukemia

Published: November 03, 2025

Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

Journal: Leukemia

Published: July 05, 2025

Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?

Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?

Journal: European cardiology

Published: May 14, 2025

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny.

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny.

Journal: British journal of pharmacology

Published: November 06, 2024

Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study.

Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study.

Journal: Frontiers in neurology

Published: September 27, 2024

Anthracyclines, Diastolic Dysfunction and the road to Heart Failure in Cancer survivors: An untold story.

Anthracyclines, Diastolic Dysfunction and the road to Heart Failure in Cancer survivors: An untold story.

Journal: Progress in cardiovascular diseases

Published: July 14, 2024

Humans and Rodents: The Case of hOAT4 and mOat5.

Humans and Rodents: The Case of hOAT4 and mOat5.

Journal: The Journal of pharmacology and experimental therapeutics

Published: May 16, 2024

Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry.

Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry.

Journal: Molecules (Basel, Switzerland)

Published: December 12, 2023

Showing 1-12 of 56

Last Updated: 09/26/2026